Final hours! Save up to 50% OFF InvestingProCLAIM SALE

UPDATE 2-Trudeau says coronavirus vaccine news is 'light at the end of the tunnel'

Published 2020-11-09, 10:49 a/m
PFE
-
BNTX
-

(Adds Canada seeking more Pfizer vaccine)

By David Ljunggren and Steve Scherer

OTTAWA, Nov 9 (Reuters) - Pfizer Inc (NYSE:PFE)'s PFE.N announcement that its experimental COVID-19 vaccine is more than 90% effective is "very encouraging" and Canada is looking to secure more doses of it, Canadian Prime Minister Justin Trudeau said on Monday.

"We hope a vaccine is coming early next year. We're seeing a light at the end of the tunnel," he told a news conference. Canada has a deal with Pfizer for a minimum of 20 million doses.

The doses could be distributed during the first quarter of next year to high priority groups, Trudeau said. Canada may get the vaccine after the United States and Britain, but at about the same time as the European Union and others, a government source said.

While Trudeau said other vaccine candidates are expected to perform well, he said Canada was looking to secure more doses of the vaccine developed by Pfizer and its German partner BioNTech SE BNTX.O .

"As for Pfizer, I know we have secured several million doses ... and obviously if it works we will buy more when they become available," he said. Trudeau added that there were logistical challenges to distributing the vaccine since it must be stored at very low temperatures.

"We don't have the infrastructure in place now to store the vaccine but I'm confident it will be in place in January," said the government source, who requested anonymity given the sensitivity of the situation. "We won't be able to get supplies into every pharmacy, certainly not immediately."

As is the case in many countries, a second wave of the novel coronavirus is sweeping across Canada, which is setting daily records for new infections. Canada has recorded 264,113 cases and 10,522 deaths so far, forcing some provinces to reimpose restrictions on gatherings and movement.

"We need to hang on - the next months are critical," Trudeau said. Canada has agreements with a number of major companies to access up to 358 million doses of their vaccine candidates.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.